Article
[ESR1 Mutation-Positive Recurrent Breast Cancer Successfully Treated with Letrozole plus Abemaciclib].
Gan to kagaku ryoho. Cancer & chemotherapy - 1 Aug 2023
Terasawa Risa, Takashima Yuko, Hirata Aoko, Kimura Kosei, Morita Shinsho, Hayashi Michihiro
Abstract excerpt
Approximately 70% of breast cancers are estrogen receptor(ER)positive, an indication for endocrine therapy. The first choice of treatment for ER-positive metastatic recurrent breast cancer is endocrine therapy, which has relatively few side effects; however, many of these side effects become resistant during treatment. One of the resistance mechanisms is mutations in the ESR1 gene, which have also been found to...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.